BTK and B-cell chronic lymphocytic leukemia: Among all new-generation BTK inhibitors, acalabrutinib is presently the most advanced drug in clinical development and demonstrates an impressive ORR of 97% (90% PR; 7% CR) in treatment-naïve CLL.